Pro-Dex, Inc. (PDEX) P/E Ratio History
ExpensiveTrading at 24.1x vs 5Y avg 16.9x · 90th percentile · Material premium to history · Data 1993–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Pro-Dex, Inc. (PDEX) trades at a price-to-earnings ratio of 24.1x, with a stock price of $64.37 and trailing twelve-month earnings per share of $3.67.
The current P/E is 43% above its 5-year average of 16.9x. Over the past five years, PDEX's P/E has ranged from a low of 9.6x to a high of 31.7x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, PDEX is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 1.97 (P/E divided by 345% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, PDEX trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PDEX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PDEX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PDEX P/E vs Peers
Surgical and interventional devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 31.6 | - | +5% | |
| $4B | 25.6 | 1.55Best | +18% | |
| $118B | 36.6 | 2.46 | +8% | |
| $17B | 24.8 | - | -20% | |
| $102B | 22.0Lowest | - | +31%Best | |
| $17B | 30.5 | - | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PDEX Historical P/E Data (1993–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | - | $49.12 | $3.62 | 13.6x | -36% |
| FY2026 Q2 | Dec 31 2025 | $38.48 | $3.40 | 11.3x | -47% |
| FY2026 Q1 | - | $33.85 | $3.35 | 10.1x | -53% |
| FY2025 Q4 | Jun 30 2025 | $43.64 | $2.70 | 16.2x | -24% |
| FY2025 Q3 | Mar 31 2025 | $49.58 | $2.80 | 17.7x | -17% |
| FY2025 Q2 | - | $46.75 | $2.01 | 23.3x | +9% |
| FY2025 Q1 | Sep 30 2024 | $29.85 | $1.54 | 19.4x | -9% |
| FY2024 Q4 | Jun 30 2024 | $19.64 | $0.62 | 31.7x | +49% |
| FY2024 Q3 | Mar 31 2024 | $17.60 | $1.21 | 14.5x | -32% |
| FY2024 Q2 | Dec 31 2023 | $17.52 | $1.38 | 12.7x | -40% |
| FY2024 Q1 | Sep 30 2023 | $15.70 | $1.48 | 10.6x | -50% |
| FY2023 Q4 | Jun 30 2023 | $19.10 | $1.98 | 9.6x | -55% |
| FY2023 Q3 | Mar 31 2023 | $16.41 | $1.31 | 12.5x | -41% |
| FY2023 Q2 | Dec 31 2022 | $15.90 | $1.07 | 14.9x | -30% |
| FY2023 Q1 | Sep 30 2022 | $17.72 | $1.08 | 16.4x | -23% |
| FY2022 Q4 | - | $15.95 | $1.03 | 15.5x | -27% |
| FY2022 Q3 | - | $16.53 | $0.88 | 18.8x | -12% |
| FY2022 Q2 | Dec 31 2021 | $23.21 | $1.26 | 18.4x | -14% |
| FY2022 Q1 | - | $25.67 | $1.09 | 23.5x | +10% |
| FY2021 Q4 | Jun 30 2021 | $30.56 | $1.13 | 26.9x | +27% |
| FY2021 Q3 | Mar 31 2021 | $26.95 | $1.52 | 17.7x | -17% |
| FY2021 Q2 | - | $30.97 | $1.32 | 23.4x | +10% |
| FY2021 Q1 | Sep 30 2020 | $28.60 | $1.55 | 18.5x | -13% |
| FY2020 Q4 | - | $17.82 | $1.50 | 11.9x | -44% |
| FY2020 Q3 | - | $16.20 | $1.09 | 14.9x | -30% |
| FY2020 Q2 | - | $17.55 | $0.96 | 18.3x | -14% |
| FY2020 Q1 | Sep 30 2019 | $15.30 | $0.93 | 16.5x | -23% |
| FY2019 Q4 | Jun 30 2019 | $12.98 | $0.97 | 13.4x | -37% |
| FY2019 Q3 | Mar 31 2019 | $14.48 | $0.80 | 18.1x | -15% |
| FY2019 Q2 | Dec 31 2018 | $12.08 | $0.74 | 16.4x | -23% |
| FY2019 Q1 | Sep 30 2018 | $10.40 | $0.54 | 19.4x | -9% |
| FY2018 Q4 | Jun 30 2018 | $6.65 | $0.38 | 17.7x | -17% |
| FY2018 Q3 | Mar 31 2018 | $6.85 | $0.52 | 13.2x | -38% |
| FY2018 Q2 | Dec 31 2017 | $6.80 | $0.63 | 10.8x | -49% |
| FY2018 Q1 | Sep 30 2017 | $7.25 | $1.33 | 5.5x | -74% |
| FY2017 Q4 | Jun 30 2017 | $6.15 | $1.25 | 4.9x | -77% |
| FY2017 Q3 | Mar 31 2017 | $4.60 | $1.11 | 4.1x | -81% |
| FY2017 Q2 | Dec 31 2016 | $4.70 | $0.98 | 4.8x | -78% |
| FY2017 Q1 | Sep 30 2016 | $4.58 | $0.30 | 15.4x | -27% |
| FY2016 Q4 | - | $5.56 | $0.20 | 28.3x | +33% |
| FY2016 Q3 | - | $3.82 | $0.17 | 22.6x | +6% |
| FY2016 Q2 | - | $2.42 | $0.06 | 38.3x | +80% |
| FY2012 Q3 | Mar 31 2012 | $2.45 | $0.21 | 11.6x | -45% |
| FY2012 Q2 | Dec 31 2011 | $2.46 | $0.62 | 4.0x | -81% |
| FY2012 Q1 | Sep 30 2011 | $2.00 | $0.83 | 2.4x | -89% |
| FY2011 Q4 | - | $2.08 | $0.79 | 2.6x | -88% |
| FY2010 Q3 | Mar 31 2010 | $1.53 | $0.35 | 4.3x | -80% |
| FY2008 Q4 | Jun 30 2008 | $3.18 | $0.10 | 31.6x | +48% |
| FY2008 Q3 | Mar 31 2008 | $4.59 | $0.28 | 16.5x | -23% |
| FY2008 Q2 | Dec 31 2007 | $4.35 | $0.32 | 13.8x | -35% |
| FY2008 Q1 | Sep 30 2007 | $4.44 | $0.18 | 24.7x | +16% |
| FY2007 Q4 | Jun 30 2007 | $4.74 | $0.16 | 30.5x | +43% |
| FY2007 Q3 | Mar 31 2007 | $4.08 | $0.17 | 24.4x | +15% |
| FY2007 Q2 | Dec 31 2006 | $4.35 | $0.10 | 42.4x | +99% |
| FY2007 Q1 | Sep 30 2006 | $4.02 | $0.24 | 16.5x | -23% |
| FY2006 Q4 | Jun 30 2006 | $5.25 | $0.25 | 21.2x | -0% |
| FY2006 Q3 | Mar 31 2006 | $7.38 | $0.45 | 16.5x | -23% |
| FY2006 Q2 | Dec 31 2005 | $7.35 | $0.53 | 13.8x | -35% |
| FY2006 Q1 | Sep 30 2005 | $10.20 | $0.49 | 20.8x | -3% |
| FY2005 Q4 | - | $10.14 | $0.56 | 18.0x | -15% |
| FY2005 Q3 | - | $8.19 | $0.43 | 18.9x | -11% |
| FY2005 Q2 | Dec 31 2004 | $8.31 | $0.43 | 19.3x | -9% |
| FY2005 Q1 | - | $7.68 | $0.45 | 17.2x | -19% |
| FY2004 Q4 | Jun 30 2004 | $5.61 | $0.36 | 15.6x | -27% |
| FY2004 Q3 | Mar 31 2004 | $8.07 | $0.25 | 31.7x | +49% |
| FY2004 Q2 | Dec 31 2003 | $9.42 | $0.19 | 49.6x | +133% |
| FY2004 Q1 | - | $4.80 | $0.11 | 45.3x | +113% |
| FY2003 Q4 | Jun 30 2003 | $3.90 | $0.04 | 92.0x | +332% |
| FY2002 Q3 | Mar 31 2002 | $3.60 | $0.65 | 5.6x | -74% |
| FY2002 Q2 | Dec 31 2001 | $2.46 | $0.65 | 3.8x | -82% |
| FY2002 Q1 | Sep 30 2001 | $3.24 | $0.83 | 3.9x | -82% |
| FY2001 Q4 | Jun 30 2001 | $3.24 | $0.97 | 3.3x | -84% |
| FY2001 Q3 | Mar 31 2001 | $7.23 | $0.17 | 42.0x | +97% |
| FY2001 Q2 | Dec 31 2000 | $8.63 | $0.40 | 21.4x | +1% |
| FY2001 Q1 | Sep 30 2000 | $6.38 | $0.63 | 10.1x | -52% |
| FY2000 Q4 | Jun 30 2000 | $7.31 | $0.52 | 14.0x | -34% |
| FY1998 Q4 | - | $5.81 | $0.12 | 46.7x | +119% |
| FY1998 Q3 | - | $6.19 | $0.27 | 22.7x | +6% |
| FY1997 Q2 | - | $7.13 | $0.16 | 45.3x | +113% |
| FY1997 Q1 | Sep 30 1996 | $11.25 | $0.28 | 40.1x | +88% |
| FY1996 Q4 | Jun 30 1996 | $12.52 | $0.55 | 22.8x | +7% |
| FY1996 Q3 | Mar 31 1996 | $13.50 | $0.35 | 38.2x | +80% |
| FY1996 Q2 | Dec 31 1995 | $10.50 | $0.23 | 45.1x | +112% |
| FY1996 Q1 | Sep 30 1995 | $6.94 | $0.26 | 26.4x | +24% |
| FY1995 Q4 | Jun 30 1995 | $8.63 | $0.18 | 47.1x | +121% |
| FY1995 Q3 | Mar 31 1995 | $8.81 | $0.30 | 29.7x | +39% |
| FY1995 Q2 | Dec 31 1994 | $6.19 | $0.30 | 20.8x | -2% |
| FY1995 Q1 | Sep 30 1994 | $7.69 | $0.33 | 23.5x | +10% |
| FY1994 Q4 | - | $6.00 | $0.36 | 16.8x | -21% |
| FY1994 Q3 | - | $8.44 | $0.17 | 49.6x | +133% |
| FY1994 Q2 | Dec 31 1993 | $5.25 | $0.26 | 20.2x | -5% |
| FY1994 Q1 | - | $6.38 | $0.17 | 37.5x | +76% |
| FY1993 Q4 | Jun 30 1993 | $7.31 | $0.14 | 52.2x | +145% |
| FY1993 Q3 | Mar 31 1993 | $6.38 | $0.39 | 16.3x | -23% |
Average P/E for displayed period: 21.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
33+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PDEX — Frequently Asked Questions
Quick answers to the most common questions about buying PDEX stock.
What is PDEX's P/E ratio?
Pro-Dex, Inc. (PDEX) trailing twelve-month P/E ratio is 24.1x, based on TTM diluted EPS of $3.67. The 5-year average P/E is 16.9x and the historical range spans 9.6x to 31.7x.
Is PDEX stock overvalued or undervalued?
PDEX trades at 24.1x P/E, above its 5-year average of 16.9x. The 90th percentile ranking within the 9.6x–31.7x historical range indicates a premium to historical valuation.
Is PDEX stock expensive?
Yes, PDEX is expensive relative to its own history. The current P/E of 24.1x is above the 5-year average of 16.9x and also above the Healthcare sector median of 22.1x. The stock sits at the 90th percentile of its 5-year valuation range.
What is PDEX's historical P/E range?
Over the past 5 years, PDEX's P/E ratio has ranged from 9.6x to 31.7x, with a median of 16.2x and an average of 16.9x. The current P/E of 24.1x places the stock at the 90th percentile of this range. Full historical data spans 1993–2026.
How does PDEX's P/E compare to the S&P 500?
PDEX trades at 24.1x P/E versus the S&P 500 median of 24.4x. The 1% discount to the market suggests lower growth expectations or perceived higher risk.
How does PDEX's valuation compare to Healthcare peers?
Pro-Dex, Inc. P/E of 24.1x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PDEX's PEG ratio?
PDEX PEG ratio is 1.97, based on a P/E of 24.1x and EPS growth of 345.0%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.
What is PDEX's earnings yield?
PDEX earnings yield is 4.15%, the inverse of its 24.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.